Management of Epilepsy in Adults: Diagnosis Guidelines

Louis F. Trost IIIa Dr Wender is on the advisory board of Enterix, GlaxoSmithKline, and Gl View. Dr Rosenberg is on the speakers’ bureau for Teva, Cephalon, Serono, and Berlex. Dr Brixner has received research support from Novartis. Dr Trost, Dr Suter, Ms Von Worley, and Dr Gunter disclose no financial interests in this article. Partial funding for guideline development was obtained from Novartis and the CDC National Center for Chronic Disease Prevention and Health Promotion.;b Dr Trost is a physician, department of family medicine, Presbyterian Medical Center, Rio Rancho, New Mexico. Dr Wender is alumni professor and chair, department of family and community medicine, Jefferson Medical College of Thomas Jefferson University, Philadelphia. Dr Suter is a neurologist, department of neurology, Lovelace Sandia Health Systems, Albuquerque. Dr Rosenberg is clinical professor of neurology and voluntary faculty, University of California, San Diego, School of Medicine, La Jolla. Dr Brixner is associate professor and chair, department of pharmacotherapy, and executive director, Pharmacotherapy Outcomes Research Center, University of Utah College of Pharmacy, Salt Lake City. Ms Von Worley is senior clinical research associate and Dr Gunter is president and executive director, Lovelace Clinic Foundation, Albuquerque. (For a complete listing of the members of the National Epilepsy Management Panel, see page 20.)

, MD,

Richard C. Wendera Dr Wender is on the advisory board of Enterix, GlaxoSmithKline, and Gl View. Dr Rosenberg is on the speakers’ bureau for Teva, Cephalon, Serono, and Berlex. Dr Brixner has received research support from Novartis. Dr Trost, Dr Suter, Ms Von Worley, and Dr Gunter disclose no financial interests in this article. Partial funding for guideline development was obtained from Novartis and the CDC National Center for Chronic Disease Prevention and Health Promotion.;b Dr Trost is a physician, department of family medicine, Presbyterian Medical Center, Rio Rancho, New Mexico. Dr Wender is alumni professor and chair, department of family and community medicine, Jefferson Medical College of Thomas Jefferson University, Philadelphia. Dr Suter is a neurologist, department of neurology, Lovelace Sandia Health Systems, Albuquerque. Dr Rosenberg is clinical professor of neurology and voluntary faculty, University of California, San Diego, School of Medicine, La Jolla. Dr Brixner is associate professor and chair, department of pharmacotherapy, and executive director, Pharmacotherapy Outcomes Research Center, University of Utah College of Pharmacy, Salt Lake City. Ms Von Worley is senior clinical research associate and Dr Gunter is president and executive director, Lovelace Clinic Foundation, Albuquerque. (For a complete listing of the members of the National Epilepsy Management Panel, see page 20.)

, MD,

Cary C. Sutera Dr Wender is on the advisory board of Enterix, GlaxoSmithKline, and Gl View. Dr Rosenberg is on the speakers’ bureau for Teva, Cephalon, Serono, and Berlex. Dr Brixner has received research support from Novartis. Dr Trost, Dr Suter, Ms Von Worley, and Dr Gunter disclose no financial interests in this article. Partial funding for guideline development was obtained from Novartis and the CDC National Center for Chronic Disease Prevention and Health Promotion.;b Dr Trost is a physician, department of family medicine, Presbyterian Medical Center, Rio Rancho, New Mexico. Dr Wender is alumni professor and chair, department of family and community medicine, Jefferson Medical College of Thomas Jefferson University, Philadelphia. Dr Suter is a neurologist, department of neurology, Lovelace Sandia Health Systems, Albuquerque. Dr Rosenberg is clinical professor of neurology and voluntary faculty, University of California, San Diego, School of Medicine, La Jolla. Dr Brixner is associate professor and chair, department of pharmacotherapy, and executive director, Pharmacotherapy Outcomes Research Center, University of Utah College of Pharmacy, Salt Lake City. Ms Von Worley is senior clinical research associate and Dr Gunter is president and executive director, Lovelace Clinic Foundation, Albuquerque. (For a complete listing of the members of the National Epilepsy Management Panel, see page 20.)

, MD,

Jay H. Rosenberga Dr Wender is on the advisory board of Enterix, GlaxoSmithKline, and Gl View. Dr Rosenberg is on the speakers’ bureau for Teva, Cephalon, Serono, and Berlex. Dr Brixner has received research support from Novartis. Dr Trost, Dr Suter, Ms Von Worley, and Dr Gunter disclose no financial interests in this article. Partial funding for guideline development was obtained from Novartis and the CDC National Center for Chronic Disease Prevention and Health Promotion.;b Dr Trost is a physician, department of family medicine, Presbyterian Medical Center, Rio Rancho, New Mexico. Dr Wender is alumni professor and chair, department of family and community medicine, Jefferson Medical College of Thomas Jefferson University, Philadelphia. Dr Suter is a neurologist, department of neurology, Lovelace Sandia Health Systems, Albuquerque. Dr Rosenberg is clinical professor of neurology and voluntary faculty, University of California, San Diego, School of Medicine, La Jolla. Dr Brixner is associate professor and chair, department of pharmacotherapy, and executive director, Pharmacotherapy Outcomes Research Center, University of Utah College of Pharmacy, Salt Lake City. Ms Von Worley is senior clinical research associate and Dr Gunter is president and executive director, Lovelace Clinic Foundation, Albuquerque. (For a complete listing of the members of the National Epilepsy Management Panel, see page 20.)

, MD,

Diana I. Brixnera Dr Wender is on the advisory board of Enterix, GlaxoSmithKline, and Gl View. Dr Rosenberg is on the speakers’ bureau for Teva, Cephalon, Serono, and Berlex. Dr Brixner has received research support from Novartis. Dr Trost, Dr Suter, Ms Von Worley, and Dr Gunter disclose no financial interests in this article. Partial funding for guideline development was obtained from Novartis and the CDC National Center for Chronic Disease Prevention and Health Promotion.;b Dr Trost is a physician, department of family medicine, Presbyterian Medical Center, Rio Rancho, New Mexico. Dr Wender is alumni professor and chair, department of family and community medicine, Jefferson Medical College of Thomas Jefferson University, Philadelphia. Dr Suter is a neurologist, department of neurology, Lovelace Sandia Health Systems, Albuquerque. Dr Rosenberg is clinical professor of neurology and voluntary faculty, University of California, San Diego, School of Medicine, La Jolla. Dr Brixner is associate professor and chair, department of pharmacotherapy, and executive director, Pharmacotherapy Outcomes Research Center, University of Utah College of Pharmacy, Salt Lake City. Ms Von Worley is senior clinical research associate and Dr Gunter is president and executive director, Lovelace Clinic Foundation, Albuquerque. (For a complete listing of the members of the National Epilepsy Management Panel, see page 20.)

, PhD, RPh,

Ann Marie Von Worleya Dr Wender is on the advisory board of Enterix, GlaxoSmithKline, and Gl View. Dr Rosenberg is on the speakers’ bureau for Teva, Cephalon, Serono, and Berlex. Dr Brixner has received research support from Novartis. Dr Trost, Dr Suter, Ms Von Worley, and Dr Gunter disclose no financial interests in this article. Partial funding for guideline development was obtained from Novartis and the CDC National Center for Chronic Disease Prevention and Health Promotion.;b Dr Trost is a physician, department of family medicine, Presbyterian Medical Center, Rio Rancho, New Mexico. Dr Wender is alumni professor and chair, department of family and community medicine, Jefferson Medical College of Thomas Jefferson University, Philadelphia. Dr Suter is a neurologist, department of neurology, Lovelace Sandia Health Systems, Albuquerque. Dr Rosenberg is clinical professor of neurology and voluntary faculty, University of California, San Diego, School of Medicine, La Jolla. Dr Brixner is associate professor and chair, department of pharmacotherapy, and executive director, Pharmacotherapy Outcomes Research Center, University of Utah College of Pharmacy, Salt Lake City. Ms Von Worley is senior clinical research associate and Dr Gunter is president and executive director, Lovelace Clinic Foundation, Albuquerque. (For a complete listing of the members of the National Epilepsy Management Panel, see page 20.)

, RN,

Margaret J. Guntera Dr Wender is on the advisory board of Enterix, GlaxoSmithKline, and Gl View. Dr Rosenberg is on the speakers’ bureau for Teva, Cephalon, Serono, and Berlex. Dr Brixner has received research support from Novartis. Dr Trost, Dr Suter, Ms Von Worley, and Dr Gunter disclose no financial interests in this article. Partial funding for guideline development was obtained from Novartis and the CDC National Center for Chronic Disease Prevention and Health Promotion.;b Dr Trost is a physician, department of family medicine, Presbyterian Medical Center, Rio Rancho, New Mexico. Dr Wender is alumni professor and chair, department of family and community medicine, Jefferson Medical College of Thomas Jefferson University, Philadelphia. Dr Suter is a neurologist, department of neurology, Lovelace Sandia Health Systems, Albuquerque. Dr Rosenberg is clinical professor of neurology and voluntary faculty, University of California, San Diego, School of Medicine, La Jolla. Dr Brixner is associate professor and chair, department of pharmacotherapy, and executive director, Pharmacotherapy Outcomes Research Center, University of Utah College of Pharmacy, Salt Lake City. Ms Von Worley is senior clinical research associate and Dr Gunter is president and executive director, Lovelace Clinic Foundation, Albuquerque. (For a complete listing of the members of the National Epilepsy Management Panel, see page 20.)

, PhD & National Epilepsy Management Panel show all

PREVIEW

In this first of two articles on new epilepsy guidelines for primary care physicians, the authors present detailed algorithms for the diagnosis and classification of seizure disorders in adults. They discuss the differentiation between generalized and partial seizures and stress that accurate identification is especially important because the type of seizure determines the appropriate treatment. The second article (page 29) looks at the treatment portion of the new guidelines.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Management of Epilepsy in Adults: Diagnosis Guidelines

Information for

Open access

Opportunities

Help and information

Management of Epilepsy in Adults: Diagnosis Guidelines

PREVIEW

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature